Results 131 to 140 of about 178,847 (197)

Designer Dynamic DNA Nanoaggregate in Living Cell for Mitochondrial Energy Restriction

open access: yesAdvanced Science, EarlyView.
This study presents the Tech‐tetrahedron, a designer dynamic DNA nanoaggregate engineered for precise mitochondrial energy restriction. Its trinity‐functionalized design integrates navigable unit, telomerase‐activated latch, and self‐assembly module.
Ruijia Deng   +12 more
wiley   +1 more source

Deletion of Lymphatic PD-L1 Protects Mice From Severe Autoimmune Encephalitis. [PDF]

open access: yesEur J Immunol
Wang Z   +8 more
europepmc   +1 more source

Placental Site Trophoblastic Tumor Acquires Immune Functions by Incorporating Host Maternal Genes

open access: yesAdvanced Science, EarlyView.
PSTT cells, through cell fusion with B cells, incorporate abundant non‐inherited maternal genes that are detectable by DNIMA. These hybrid cells acquire immunotherapy‐resistant genetic changes and increase the expression of B cell‐derived immune‐related molecules such as Ig, HLA, LILRB, SIGLEC10, and so on, creating an immunotolerant environment around
Kyosuke Kagami   +15 more
wiley   +1 more source

Heterogeneity of macrophages in PD-1/PD-L1 inhibitor therapy: a single-cell perspective. [PDF]

open access: yesCell Mol Biol Lett
Wu J   +7 more
europepmc   +1 more source

Endobody: Genetically Encodable Nanobody‐CPP Chimeras for Degradation of Membrane and Extracellular Proteins

open access: yesAdvanced Science, EarlyView.
We introduced genetically encodable, receptor‐independent nanobody‐CPP chimeras, termed endobodies, as robust and modular membrane protein degraders. Additionally, proteasome‐targeting domain (PTD)‐tethered endobody demonstrates further enhanced degradation potency.
Chengjian Zhou   +3 more
wiley   +1 more source

Engineering T cells with a novel PD-L1-specific TCR targeting immune and cancer cells. [PDF]

open access: yesSignal Transduct Target Ther
Lisle TL   +5 more
europepmc   +1 more source

Single‐Cell Reveal GALNT7‐Dependent Ferroptosis Suppression as a Mechanism of Immunotherapy Resistance in Non‐Small Cell Lung Cancer

open access: yesAdvanced Science, EarlyView.
Integrated clinical and mechanistic analyses identify GALNT7 as a ferroptosis‐suppressive regulator associated with immunotherapy resistance in non‐small cell lung cancer. GALNT7 depletion promotes lipid peroxidation, mitochondrial dysfunction, and ferroptosis, enhances CD8+ T‐cell activation and IFN‐γ production, and sensitizes tumors to PD‐1 blockade,
Jiadi Gan   +11 more
wiley   +1 more source

Differentiation state affects PD-L1 expression in cutaneous melanoma: a systematic review. [PDF]

open access: yesCell Mol Biol Lett
Sævarsson T   +3 more
europepmc   +1 more source

Membrane Fusion‐Mediated Cytosolic Delivery of Threose Nucleic Acids via Homotypic Nanoparticles Overcomes Drug Resistance in Triple‐Negative Breast Cancer

open access: yesAdvanced Science, EarlyView.
This study introduces a biomimetic “nanofusion” platform that integrates the biostability of threose nucleic acids (TNA) with homotypic cell‐membrane cloaking to combat drug‐resistant TNBC. By leveraging a non‐canonical membrane‐fusion pathway for direct cytosolic delivery, the platform bypasses endosomal sequestration. To achieve potent AKT2 silencing
Wei Zheng   +7 more
wiley   +1 more source

Strategies to target PD-1/PD-L1 in the tumor microenvironment. [PDF]

open access: yesCell Oncol (Dordr)
Kui Y, Tong F, Zhang R, Dong X, Wang J.
europepmc   +1 more source

Home - About - Disclaimer - Privacy